Directed Drug Convection Using Magnetic Nanoparticles as Therapeutic Carriers Meeting the Challenge of Specific Brain Pharmacotherapeutics, Non-ligand-Based Central Nervous System Targeting, Including Magnetic Focusing
-
1.
California Institute of Technology
- 2. Chairman, CEO and Scientific Director, Society for Brain Mapping & Therapeutics (SBMT), Pacific Palisades, CA, USA
- 3. President and Scientific Director, World Brain Mapping Foundation (WBMF), Pacific Palisades, USA
- 4. Director of National Center for Nano-Bio-Electronics (NCNBE), Los Angeles, USA
- 5. Director of Brain Technology and Innovation Park (BTIP), Los Angeles, USA
- 6. Chairman, Neuroscience20 (Brain, Spine, Mental Health) Initiative, Los Angeles, USA
- 7. CEO and Co-founder, Aramis Therapeutics, Los Angeles, CA, USA
-
8.
Tulane University
-
9.
University of Manitoba
-
10.
Kent State University
-
11.
Health Sciences Centre
-
12.
Case Western Reserve University
-
13.
Aeromics (United States)
-
14.
Texas Neurology
-
15.
Baylor Scott & White Health
Abstract
This chapter, titled “Directed Drug Convection Using Magnetic Nanoparticles,” explores the use of magnetic nanoparticles for precise drug delivery in the central nervous system (CNS). Magnetic nanoparticles can be guided by external magnetic fields, enabling targeted drug delivery within the brain. The chapter covers applications in treating neurological diseases and controlled drug release. While highlighting the potential of magnetic nanoparticles, it addresses considerations like biocompatibility and safety. In summary, this chapter underscores how magnetic nanoparticles enhance CNS pharmacotherapeutics, offering more effective treatments for neurological disorders.
Copyright and License
© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG
Files
| Name | Size | Download all |
|---|---|---|
|
md5:7c0bc81dc0afce572b32005d5adeef41
|
1.7 MB | Preview Download |
Additional details
- Publication Status
- Published